Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117,” presented by Mikkael A. Sekeres, MD, MS.
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormali...
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinic...
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,